FY2024 EPS Estimates for Teleflex Raised by Zacks Research

Teleflex Incorporated (NYSE:TFX - Free Report) - Stock analysts at Zacks Research increased their FY2024 earnings estimates for Teleflex in a research report issued on Thursday, November 7th. Zacks Research analyst R. Department now forecasts that the medical technology company will post earnings per share of $13.97 for the year, up from their previous forecast of $13.88. The consensus estimate for Teleflex's current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex's Q1 2025 earnings at $3.54 EPS, Q3 2025 earnings at $3.78 EPS, Q4 2025 earnings at $4.22 EPS, FY2025 earnings at $15.27 EPS and Q1 2026 earnings at $4.17 EPS.

Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, beating the consensus estimate of $3.38 by $0.11. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The business had revenue of $764.40 million during the quarter, compared to analyst estimates of $768.68 million. During the same quarter last year, the firm posted $3.64 earnings per share. The business's revenue for the quarter was up 2.4% compared to the same quarter last year.

Several other research firms have also recently commented on TFX. Truist Financial reiterated a "hold" rating and set a $227.00 price target (down previously from $255.00) on shares of Teleflex in a report on Monday, November 4th. Stephens boosted their price target on shares of Teleflex from $275.00 to $290.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Teleflex in a report on Friday, November 1st. Mizuho lowered their price target on shares of Teleflex from $275.00 to $250.00 and set a "neutral" rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada reduced their price objective on shares of Teleflex from $275.00 to $245.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $259.25.

Teleflex Stock Up 1.3 %

Shares of NYSE TFX traded up $2.52 during midday trading on Monday, hitting $198.07. The company's stock had a trading volume of 501,972 shares, compared to its average volume of 377,551. The business's fifty day simple moving average is $235.39 and its two-hundred day simple moving average is $223.87. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. Teleflex has a 1 year low of $194.58 and a 1 year high of $257.85. The firm has a market capitalization of $9.20 billion, a price-to-earnings ratio of 39.51, a price-to-earnings-growth ratio of 2.00 and a beta of 1.18.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be given a $0.34 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.36 annualized dividend and a yield of 0.69%. Teleflex's dividend payout ratio (DPR) is 27.04%.

Insider Activity at Teleflex

In related news, Director Stuart A. Randle sold 2,674 shares of the company's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $238.93, for a total value of $638,898.82. Following the completion of the sale, the director now owns 5,496 shares in the company, valued at $1,313,159.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.43% of the stock is owned by insiders.

Institutional Trading of Teleflex

Several institutional investors and hedge funds have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund raised its position in Teleflex by 1.2% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,021 shares of the medical technology company's stock worth $846,000 after buying an additional 46 shares during the last quarter. Cromwell Holdings LLC raised its position in Teleflex by 59.0% during the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company's stock worth $33,000 after buying an additional 49 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in Teleflex by 1.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 2,779 shares of the medical technology company's stock worth $584,000 after buying an additional 53 shares during the last quarter. Apollon Wealth Management LLC raised its position in Teleflex by 3.7% during the 3rd quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company's stock worth $377,000 after buying an additional 55 shares during the last quarter. Finally, SRS Capital Advisors Inc. raised its position in Teleflex by 0.3% during the 3rd quarter. SRS Capital Advisors Inc. now owns 19,587 shares of the medical technology company's stock worth $4,844,000 after buying an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company's stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.